Francesca Zammarchi

Francesca Zammarchi

Company: Myricx Bio

Job title: Chief Scientific Officer


Panel: Considering Future Clinical Applicability of Novel Payloads Currently in Discovery

Chairs: 1:45 pm

Thinking about the future of the clinical landscape in comparison to now, and what the most promising novel payload contenders are Realizing feasibility of some novel payloads: thinking about developmental or future safety concerns with novel mechanisms of action Identifying gaps for development of novel payloads from the current landscapeRead more

day: Conference Day Two

Validating N-Myristoyltransferase Inhibitor as a Novel Payload Class for ADCs: Exploring Myricx Bio’s Pre-Clinical Efficacy Studies with NMTi as Payload Platform 12:30 pm

N-Myristoyltransferase (NMT) as a drug target in cancer Development of NMT inhibitors (NMTi) as a Novel Payload Class for ADCs: case studies with NMTi-ADCs targeting B7-H3, TROP2 and HER2 Advancing Myricx Bio’s NMTi-ADC pipeline for the treatment of solid tumorsRead more

day: Conference Day One

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.